(Q80101008)

English

DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial

scientific article published on 01 November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

multicenter clinical trial

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Paul Ellis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David Dunlop

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Malcolm Ranson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sarah Danson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Lee Schacter

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Denis Talbot

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

984-990

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Uptake of plasma lipids by tissue-isolated hepatomas 7288CTC and 7777 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour-host metabolic interrelationships

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor targeting by conjugation of DHA to paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931631-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1556-0864(15)31631-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409983%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80101008&oldid=1949171979"